Exelixis (EXEL)
Develops and commercializes cancer medicines around cabozantinib and a broader oncology pipeline.
Something off on this page? Send us feedback.
Sells CABOMETYX and COMETRIQ directly in the United States and earns collaboration revenue from partner-marketed medicines abroad. One oncology-focused segment remains centered on cabozantinib while zanzalintinib and earlier small-molecule and antibody-based programs are developed as potential additional franchises.
Discovers, develops, and commercializes cancer medicines, with CABOMETYX and COMETRIQ sold directly in the United States and COTELLIC and MINNEBRO handled through partners. The business reports as one oncology-focused segment.
Uses its U.S. cabozantinib franchise and licensing relationships abroad to fund the next pipeline. Zanzalintinib is the lead next-generation oral kinase inhibitor, while earlier programs span small molecules and antibody-based therapies.
Execution has centered on redirecting cabozantinib into kidney, liver, and thyroid cancer settings after an earlier prostate-cancer trial setback. Revenue remains concentrated in CABOMETYX, and the model depends on continued demand, successful clinical and regulatory development, durable intellectual property, and partner performance outside direct territories.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 18, 2026 | BMO Capital | Initiate | Rating: —Target: $36 | Target: $54 |
| Aug 6, 2026 | Leerink Partners | Target | Target: $48 | Target: $52 |
| Aug 6, 2026 | Truist Financial | Target | Target: $54 | Target: $52 |
| Aug 3, 2026 | UBS | Target | Target: $52 | Target: $55 |
| Jul 23, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $49 | Target: $53 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 3, 2026Cash & short-term investments $839.4M · Total debt $165.9M · Total assets $2.49B · Shareholders' equity $1.84B
- Revenue
- $628.7M
- Operating income
- $248.4M
- Net income
- $212.1M
No dividends on record.
| Institutions | ≥ 95.83% | 237.44M shares | |
|---|---|---|---|
| 779 holders · as of Jun 30, 2026 · largest filers only | |||
| Insiders | 2.10% | 5.20M shares | |
| 15 holders · as of Aug 12, 2026 | |||
| Other | ≤ 2.07% | 5.14M shares | |
| remainder | |||
247.78M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the 99 largest filers, so at least this.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 11.73% | 29.08M | as of Jun 30, 2026 |
Farallon Capital Management LLCInstitution | 5.44% | 13.47M | as of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 5.42% | 13.43M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.86% | 12.04M | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 4.45% | 11.02M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 10, 2026 | Mary C. Beckerle | director | −9,812 | $53.66 |
| Jun 1, 2026 | Sue Gail Eckhardt | director | −9,812 | $50.14 |
| Jun 1, 2026 | Jack L. Wyszomierski | director | −3,925 | $50.55 |
| May 26, 2026 | Dana Aftab | officer: EVP, Research and Development | −43,451 | $50.35 |
| May 20, 2026 | Patrick J. Haley | officer: EVP, Commercial | −32,110 | $49.81 |
- Merck
Broad kidney-cancer rival across immunotherapy and oral agents
- Bristol-Myers Squibb
Checkpoint regimens overlap in kidney and liver cancers
- Pfizer
INLYTA and SUTENT contest renal and pancreatic NET markets
- Novartis (ADR)
AFINITOR and LUTATHERA overlap in renal and neuroendocrine tumors
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Exelixis | $58.57 | +2.36% | $14.38B | 17.9 | 15.8 | 5.9 | +10.6% |
| Merck | $152.18 | +1.79% | $369.24B | 119.6 | 17.6 | 5.6 | +5.1% |
| Bristol-Myers Squibb | $62.70 | +0.12% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Pfizer | $27.77 | +0.09% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| Novartis (ADR) | $141.17 | +0.13% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Median | 29.0 | 12.5 | 3.7 | +3.8% |